Bright Minds Biosciences Inc (DRUG)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Bright Minds Biosciences Inc (DRUG) is down 6.1% since the beginning of the year. At $73 per share, DRUG is trading 40.8% below its 52-week high of $124. Investors who bought $1,000 worth of DRUG shares 5 years ago would now be looking at an investment worth $3,117.

Bright Minds Biosciences Inc (DRUG) has returned -6.13% so far this year and 117.84% over the past 12 months.

Based on dividend-adjusted daily data since Mar 22, 2021, DRUG's average daily return is +1.23%, while the average monthly return is +58.93%. At this rate, an investment would double in approximately 0.1 years.

Historically, 43% of months were positive and 57% were negative. The best month was Oct 2024 with a return of +3,900.0%, while the worst month was Aug 2023 at -48.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, DRUG closed higher 41% of trading days. The best single day was Oct 15, 2024 with a return of +1,445.8%, while the worst single day was Aug 19, 2022 at -42.4%.

Bright Minds Biosciences Inc has an annualized alpha of 2024.42%, beta of 0.23, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since March 22, 2021.

• This stock captured 59.07% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -7.16%) - a profile typical of hedging or uncorrelated assets.
• Beta of 0.23 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

DRUG ranks 85 for risk / return — above 85% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Bright Minds Biosciences Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bright Minds Biosciences Inc was 97.68%, occurring on Jul 11, 2024. Recovery took 70 trading sessions.

The current Bright Minds Biosciences Inc drawdown is 23.68%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Bright Minds Biosciences Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Bright Minds Biosciences Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.